Remixed- Path to KOLs: The New Chemist Podcast’s Global Journey in Science, Pharma, and Education: Interview with Mohan Uttarwar, CEO & Co-Founder of 1Cell.Ai

---In this episode we provide and educational episode remix made with software assistance ( for educational purposes only) , we sit down with Mohan Uttarwar, CEO & Co-Founder of 1Cell.Ai, to explore how AI-driven single-cell analytics are revolutionizing precision oncology. Discover how the OncoIncytes platform merges ctDNA, live CTCs, single-cell RNA and proteomics for a real-time, multimodal tumor profile—and learn how these insights are sharpening patient selection, accelerating ADC trials, and delivering earlier, more accurate measures of therapeutic response. Mohan also shares his playbook for building a capital-efficient biotech across Silicon Valley and India, the emerging trends set to reshape drug development, and practical advice for chemists, data scientists, and founders looking to break into the field. Tune in this August for a deep dive into the future of cancer research and drug discovery.--

Please note: The views of this podcast represent those of my guest(s) and I, and do not constitute professional or medical advice or consultation. Please see a medical professional or healthcare professional for advice, suggestions and consultations. We disclaim any loss in any way.

Music citation: Open source

The Path to KOLs: Nobel Lecture Compendium ( 100+) with AI-Powered Overviews

In this episode, we compile over 100+ Nobel Lectures and key lectures and use AI LLMs to produce video overviews of those lectures.

Please note: The views of this podcast represent those ofmy guest and I, and do not constitute medical, professional or financial advice or consultation. Please refer to the state and board-certified professionals. We disclaim any loss in any way.

Episode Description: In this episode, we sit down with Sam Libby, President and Managing Director at TCB Capital Advisors, whose career has been dedicated to transforming healthcare through strategic investments and partnerships. With more than 30 completed transactions —spanning mergers and acquisitions, capital raises, and innovative deal structures—Sam has become a trusted advisor at the intersection of finance, science, and patient care. Our conversation dives deep into his origin story—fromRutgers to leading one of the most dynamic advisory firms in healthcare—and explores how his investment philosophy balances patient-centered missions with the financial discipline demanded by markets. Sam shares case studiesfrom groundbreaking ventures like Clairity, the first FDA-cleared AI breast cancer risk platform, and Altoida, a pioneer in early cognitive assessment technology, offering valuable lessons for founders and investors alike.

We also discuss the critical role of strategic partnerships, the evolving dynamics between founders and investors, and the exciting frontiers shaping the future of healthcare—from oncology and neurodegeneration to women’s health and digital innovation. Sam highlights how AI and data are reshaping deal-making, due diligence, and commercialization pathways. Finally, Sam offers practical advice for aspiring thought leaders and entrepreneurs on refining their pitch, stepping into leadership beyond the lab, and positioning themselves for long-term impact in arapidly evolving industry.

Whether you’re a scientist, entrepreneur, investor, orfuture healthcare leader, this episode provides insightful perspectives on the business of innovation, the art of deal-making, and the mission to improvepatient outcomes.

Music citation: open source classical music

Please note: The views of this podcast represent those of my guest and I, and do not constitute medical, professional or financial advice or consultation. Please refer to the state and board-certified professionals. We disclaim any loss in any way.

🎙️ Episode Description

In this episode, we sit down with Sam Libby,President and Managing Director at TCB Capital Advisors, whose career has been dedicated to transforming healthcare through strategic investments andpartnerships. With more than 30 completed transactions —spanning mergers and acquisitions, capital raises, and innovative deal structures—Sam has become a trusted advisor at the intersection of finance, science, and patient care. Our conversation dives deep into his origin story—from Rutgers to leading one of the most dynamic advisory firms in healthcare—and explores how his investment philosophy balances patient-centered missions withthe financial discipline demanded by markets. Sam shares case studies from groundbreaking ventures like Clairity, the first FDA-cleared AI breast cancer risk platform, and Altoida, a pioneer in early cognitive assessment technology, offering valuable lessons for founders and investors alike.

We also discuss the critical role of strategicpartnerships, the evolving dynamics between founders and investors, and the exciting frontiers shaping the future of healthcare—from oncology and neurodegeneration to women’s health and digital innovation. Sam highlights how AI and data are reshaping deal-making, due diligence, and commercialization pathways.

Finally, Sam offers practical advice for aspiringthought leaders and entrepreneurs on refining their pitch, stepping into leadership beyond the lab, and positioning themselves for long-term impact in a rapidly evolving industry. Whether you’re a scientist, entrepreneur, investor, or future healthcare leader, this episode provides insightful perspectives on the business of innovation, the art of deal-making, and the mission to improvepatient outcomes.

A Highly Ranked Episode for the Overall Group: TNCPG Remix-Fireside Chat Remix - Interview with Simar Bajaj (Harvard University) ( Re-aired)

----In this fireside chat remixed episode and podcast interview with Simar, a Marshall Scholar and graduate of Harvard University, we discuss Simar's achievements in science communication, his perseverance, and the hard work required to produce good work, science communication, and good journalism. Furthermore, Simar provides insights as he is a developing and achieving young leader in the science and journalism arenas. Definitely an episode worth listening to!Here are the links to his website and LinkedIn Page:1. Simar's website: https://www.simarbajaj.com/2. Simar's LinkedIn: https://www.linkedin.com/in/simar-bajaj/----Note: The views of this podcast represent those of my guest(s) and I.Note: Purpose of these episodes- not at all, for advice or medical suggestions. These are aimed to provide support for peer pharmacists in training in educational andintellectually stimulating ways. Again, these are not at all for medical advice, or for medical suggestions. Please see your local state and board-certified physician, PA or NP, and pharmacist for medical advice andsuggestions.---Recorded in 2023

In this episode of The New Chemist’s Podcasting Group’s — The Path to KOLs, host David Ferguson sits down with Christine Hollis, Chief Talent & Diversity Officer at Marshall Gerstein. Christine has dedicated her career to guiding scientists and engineers into impactful roles within intellectual property law, bridging the worlds of innovation and legal protection.

She shares insights on:

• Pathways for STEM talent to enter IP law as patent agents or technical specialists.

• The skills scientists bring to legal environments and innovation ecosystems.

• Strategies for diversity, equity, and inclusion in science-driven law.

• The future of STEM-law collaboration in an era of AI, biotech, and medtech.

Whether you’re a student, scientist, or innovator, Christine’s vision will broaden your perspective on how STEM expertise can shape industries beyond the lab.

Disclaimer: These episodes do not constitute medical or professional advice. These are only for intellectual engagement. Please see your local and board-certified health professional for medical advice, consultation, and suggestions.

Music by Viacheslav Starostin from Pixabay

The New Chemist’s Podcasting Group — The Path to KOLs: Accelerating First-in-Human in LATAM — Julio G. Martinez-Clark, CEO, bioaccess® w/ Chadwin Hanna, MD-PhD Student (UF) and David Ferguson (Host)

---

On The Path to KOLs from The New Chemist’s Podcasting Group, hosts David Ferguson and Chadwin Hanna explore how Latin America is becoming a strategic engine for high-quality, cost-effective clinical research.

Julio G. Martinez-Clark—Ambassador of IAOCR/GCSA Americas and CEO of bioaccess®—breaks down how aligning to global competence standards and smarter site activation can compress timelines for First-in-Human and Early Feasibility Studies without compromising quality. He shares lessons from pioneering trials, practical blueprints for building city-level clinical hubs, and pragmatic guidance for innovators entering LATAM markets. The conversation also touches on sustaining regional infrastructure, cross-border collaboration, and the mindset behind his long-running Global Trial Accelerators™ series.

Guest: Julio G. Martinez-Clark, CEO, bioaccess®
Hosts: David Ferguson, BS, MS, Pharm.D. Candidate; Chadwin Hanna, MD Candidate & PhD Student

Please note: The views of this podcast reflect those of my guest(s) and I, and do not constitute medical advice, consultation and suggestions. Please see a board certified and state licensed medical professional.

The New Chemist’s Podcasting Group: The Path to KOLs — Interview with Dr. Michael A. Morris, MD, MS, DABR, DABNM, DCI — Co-Founder, United Theranostics

---

🎙️ In this episode of The Path to KOLs, Dr. Michael A. Morris, MD, MS, DABR, DABNM, DCI—co-founder of United Theranostics—explains how his team is moving Pluvicto from single mega-centers into safe, consistent community clinics. We dig into the toughest regulatory and logistical hurdles, the playbook for dosing accuracy, imaging quality, and safety, and how clinics are designed for a compassionate, family-centered patient journey with real-world feedback loops.

Dr. Morris also shares how United Theranostics trains local technologists, pharmacists, and nurses, mentors future KOLs, and maps a path to coverage across all 50 states. Looking ahead, we discuss what’s beyond Pluvicto—including actinium-225 PSMA approaches—and how telehealth, remote monitoring, and AI are improving patient selection, follow-up, and outcomes.

About the guest: Dr. Morris is a physician-scientist in nuclear medicine, diagnostic radiology, and clinical informatics; Medical Director in Glen Burnie, MD; adjunct faculty at the University of Miami and University of Maryland; and a principal investigator on multiple FDA clinical trials in prostate cancer and neuroendocrine tumors.

Subscribe for actionable insights at the intersection of innovation, operations, and patient-centered care.

Music by Dmitrii Kolesnikov from Pixabay

Please note: The views of this podcast reflect those of my guest(s) and I, and do not constitute in any way medical advice or consultation. Please see a board and state certified medical professional for advice, consultation and suggestions.